跳至主要内容
临床试验/NCT03654144
NCT03654144Unknown4 期

Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis

Assiut University0 个研究点目标入组 100 人开始时间: 2018年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
100
主要终点
The mean pain score after receiving treatment

研究概览

简要总结

Adenomyosis was first described as endometrial glands in the myometrium of the uterus. The current definition of adenomyosis is provided in 1972 'the benign invasion of endometrium into the myometrium, producing a diffusely enlarged uterus which microscopically exhibits ectopic non-neoplastic, endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • symptomatic adenomyosis
  • irregular menstrual bleeding and dysmenorrhea .

排除标准

  • asymptomatic patients -
  • non-lactating patient
  • not desire for pregnancy
  • no hormonal treatment more than 6 month even contraception e.g IUD
  • no focal lesion of uterus (malignancy ,fibroid or adenxal mass )

研究组 & 干预措施

Study group

Experimental

women will receive dienogest

干预措施: Dienogest (Drug)

control group

Active Comparator

women used combined oral contraceptive pills

干预措施: Combined Oral Contraceptive (Drug)

结局指标

主要结局

The mean pain score after receiving treatment

时间窗: 6 months

assessment by visual analog scale

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

asmaa mohamed hussin yousef

Principal investigator

Assiut University

相似试验